Connexin 43 as a Prognostic Biomarker in Ewing Sarcoma
Author Information
Author(s): Bui Marilyn M., Han Gang, Acs Geza, Reed Damon, Gonzalez Ricardo J., Pasha T. L., Zhang Paul J.
Primary Institution: Moffitt Cancer Center
Hypothesis
The expression of connexin 43 (Cx43) and connexin 26 (Cx26) in Ewing sarcoma (EWS) and primitive neuroectodermal tumor (PNET) correlates with patient outcomes.
Conclusion
Higher levels of Cx43 expression are associated with poorer overall survival in patients with Ewing sarcoma.
Supporting Evidence
- Cx43 was expressed in 78% of the EWS/PNET cases studied.
- Higher Cx43 scores correlated with shorter overall survival at both 3 and 5 years.
- Patients with metastasis had significantly poorer overall survival compared to those without.
Takeaway
This study found that a protein called Cx43 is often found in Ewing sarcoma tumors, and more of it means patients might not live as long.
Methodology
The study analyzed tissue samples from 36 patients with EWS/PNET for Cx43 and Cx26 expression and correlated these findings with clinical outcomes.
Limitations
The sample size is limited to 36 patients, which may affect the power of the statistical analyses.
Participant Demographics
The study included 36 patients diagnosed with EWS/PNET, primarily affecting children and young adults.
Statistical Information
P-Value
p=0.004
Confidence Interval
95% CI from 701 days to infinity
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website